September 9, 2026
New data presented in long-chain fatty acid oxidation disorders at INFORM 2026 support development …
MitoAction in the News
First-Ever Mitochondrial Disease Advocacy Coalition Launched,Uniting 17 Groups Behind a Single Voice on Capitol Hill
September 3, 2026
New coalition brings together organizations from across the mitochondrial disease community to …
Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND
August 25, 2026
PX578, a potentially disease-modifying, first-in-class investigational medicine cleared to start …
Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name Honoring the Mitochondrial Disease Community
June 16, 2026
NEEDHAM, Mass., June 16, 2026 — Stealth BioTherapeutics Holdings Inc., a commercial-stage biotechnology …
Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease
April 16, 2026
NOTES TO EDITORSAbout KhondrionKhondrion is a late-stage clinical biopharmaceutical company focused …
